NCT04514484进行中（未招募）1 期
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 8
- 试验地点
- 5
- 主要终点
- Incidence of dose limiting toxicities (DLTs)
研究概览
简要总结
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may shrink or stabilize cancer in patients undergoing treatment for HIV.
详细描述
PRIMARY OBJECTIVES:
I. To determine the safety of combined nivolumab and cabozantinib s-malate (XL184 [cabozantinib]) in human immunodeficiency virus (HIV) patients with advanced solid tumors.
II. To determine the feasibility to deliver the combined nivolumab and XL184 (cabozantinib) for a minimum of 4 cycles in at least 75% of the subjects in the expanded cohort with Kaposi sarcoma (KS) or to achieve a confirmed objective response.
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity in subjects with Kaposi sarcoma (KS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >= 18 years. Children are excluded from this study, but will be eligible for future pediatric trials
- •For the six-patient safety cohort, subjects must have histologically or cytologically confirmed advanced solid tumors that are metastatic or recurrent, and require palliative systemic treatment, for which there are either Food and Drug Administration (FDA) approved indications for XL184 (cabozantinib) or nivolumab or have at least phase 2 data clearly indicating activity (such as renal cell carcinoma [RCC], hepatocellular carcinoma [HCC], medullary thyroid carcinoma [MTC], melanoma, non-small cell lung cancer [NSCLC], head and neck cancer, urothelial carcinoma, small cell lung cancer [SCLC], radioiodine-refractory differentiated thyroid cancer, ovarian cancer, castration-resistant prostate carcinoma [CRPC], and triple-negative breast cancer [TNBC]). Subjects must have progressed, or are intolerant, or decline systemic therapy associated with clinically significant survival benefit if checkpoint blockade is not an approved or accepted treatment. The expansion cohort is limited to subjects with KS. Histologic, cytologic, and pathologic confirmation of KS is required
- •Any number of prior cancer therapies will be permitted, including treatment naive subjects. (Note: For KS, treatment naive asymptomatic subjects will be permitted. But treatment naive KS subjects with visceral symptomatic disease or complicated KS HHV 8 disease including Castleman's disease will be excluded and should receive front-line standard of care)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Karnofsky >= 80%)
- •Subjects with tumors other than KS must have evaluable disease
- •Absolute neutrophil count >= 1,000/mcL
- •Platelets >= 75,000/mcL
- •Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (If, however, the participant has Gilbert's disease or unconjugated hyperbilirubinemia that is considered to be secondary to antiretroviral therapy, then the total bilirubin must be =< 3 x ULN)
- •Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
- •Creatinine =< 1.5 institutional ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula)
- •Hemoglobin >= 9 g/dL
- •CD4 count >= 50/mcL
- •Subjects must have known HIV infection as below: Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western blot, or any other federally approved licensed HIV test. Alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and Western blot, or other approved diagnostic tests. Subjects must receive appropriate care and treatment for HIV infection. An eligible patient should be on anti-retroviral therapy (ART) that is not strongly CYP3A4 inhibiting or otherwise prohibited by the protocol (e.g. drug-drug interactions) or the patient must be converted to one of these regimens before starting investigational therapy in order to avoid dose modulation of cabozantinib
- •Life expectancy of >= 12 weeks
- •For subjects with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- •Subjects with a history of hepatitis C virus (HCV) infection must have been treated and cured including self-cured cases. For subjects with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- •Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- •The effects of nivolumab and XL184 (cabozantinib) on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP should use an adequate method to avoid pregnancy for 5 months after the last dose of investigational drug. WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of receiving the first dose of the study medication. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception
- •Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL
- •Ability to understand and the willingness to sign a written informed consent document. Subjects with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
排除标准
- •For the safety run-in cohort, subjects who have received prior XL184 (cabozantinib), PD-1/PD-L1 inhibitor, or VEGFR inhibitor are ineligible. Prior treatment with these agents is allowed for the expansion KS cohort
- •Subjects on potent CYP3A4-inhibiting agents are ineligible, such as:
- •Antiretroviral: ritonavir, cobicistat, indinavir, atazanavir, delavirdine
- •Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin
- •Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole, posaconazole
- •Antidepressants: nefazodone
- •Antidiuretic: conivaptan
- •Gastrointestinal (GI): cimetidine, aprepitant
- •Hepatitis C: boceprevir, telaprevir
- •Miscellaneous: Seville oranges, grapefruit, or grapefruit juice and/or pummelos, star fruit, exotic citrus fruits, or grapefruit hybrids Of note, to meet the eligibility requirement, subjects are allowed to convert their antiretroviral medications to one of the regimens not including potent CYP3A4-inhibiting agents, when the subjects have progressed, are intolerant, or decline the standard systemic therapy for their advanced tumors.
- •Subjects must receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated (including no ART) and should be under the care of a physician experienced in HIV management. Subjects will be eligible provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 8 weeks following study entry.
- •To enroll in the study, the participants should be on the protocol accepted ART as long as they are receiving XL184 (cabozantinib)
- •Subjects who have had cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment, or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier
- •The subject has received radiation therapy:
- •To the thoracic cavity, abdomen, or pelvis within 4 weeks before the first dose of study treatment, or has ongoing complications, or is without complete recovery and healing from prior radiation therapy
- •To bone or brain metastases within 14 days before the first dose of study treatment
- •To any other site(s) within 21 days before the first dose of study treatment
- •Subjects who are receiving any other investigational agents
- •Subjects must be either off corticosteroids, or on a stable or decreasing dose of =< 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to enrollment. Inhaled or topical steroids are permitted in the absence of active autoimmune disease
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or XL184 (cabozantinib)
- •The subject has prothrombin time (PT)/ international normalized ratio (INR) or partial thromboplastin time (PTT) test >= 1.3 x the laboratory ULN within 7 days before the first dose of study treatment
- •The subject has a primary brain tumor, active brain metastases or epidural disease. Subjects with brain metastases previously treated with whole brain radiation or radiosurgery or participants with epidural disease previously treated with radiation or surgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Subjects with treated brain metastasis should not take enzyme-inducing anticonvulsive therapies (EIACDs) within 2 weeks of registration, though non-enzyme inducing anticonvulsive drugs such as levetiracetam are allowed. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced CT or MRI scans for participants with known brain metastases is required to confirm eligibility. Subjects with untreated central nervous system (CNS) metastases are eligible if they are not symptomatic and the lesions are less than 1 cm in size. CNS metastases should be stable for at least 4 weeks, neurologically asymptomatic and without corticosteroid treatment at time of first dose of study treatment
- •Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:
- •Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH)
- •Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
- •The subject has experienced any of the following:
- •Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment
- •Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment
- •Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
- •The subject has radiographic evidence of cavitating pulmonary lesion(s)
- •The subject has tumor in contact with, invading, or encasing any major blood vessels
- •The subject has evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first treatment
- •The subject has uncontrolled and significant cardiovascular disorders:
- •Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening
- •Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment
- •The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before treatment
- •Note: If initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard
- •Any of the following within 6 months before the first dose of study treatment:
- •Unstable angina pectoris
- •Clinically-significant cardiac arrhythmias
- •Myocardial infarction
- •Subjects with a venous filter (e.g. vena cava filter) are not eligible
- •Thromboembolic event
- •The subject has uncontrolled and significant disorders particularly those associated with a high risk of perforation or fistula formation including:
- •Any of the following within 28 days before the first dose of study treatment:
- •Active and symptomatic peptic ulcer disease
- •Evidence of active or acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study
- •Any of following within 6 months before the first dose of study treatment:
- •Abdominal fistula
- •Gastrointestinal perforation
- 另有 9 项未显示
研究组 & 干预措施
Treatment (cabozantinib s-malate, nivolumab)
Experimental
Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.
干预措施: Magnetic Resonance Imaging (Procedure)
Treatment (cabozantinib s-malate, nivolumab)
Experimental
Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.
干预措施: Cabozantinib S-malate (Drug)
Treatment (cabozantinib s-malate, nivolumab)
Experimental
Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.
干预措施: Biospecimen Collection (Procedure)
Treatment (cabozantinib s-malate, nivolumab)
Experimental
Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.
干预措施: Computed Tomography (Procedure)
Treatment (cabozantinib s-malate, nivolumab)
Experimental
Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.
干预措施: Nivolumab (Biological)
结局指标
主要结局
Incidence of dose limiting toxicities (DLTs)
时间窗: 28 days
DLTs will be defined during cycle 1 of therapy.
次要结局
- Immune status(Up to 16 weeks post treatment)
- Human immunodeficiency virus (HIV) viral loads(Up to 16 weeks post treatment)
研究者
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsBladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaBladder Urothelial CarcinomaInvasive Bladder Plasmacytoid Urothelial CarcinomaInvasive Bladder Sarcomatoid Urothelial CarcinomaInvasive Sarcomatoid Urothelial CarcinomaKidney Medullary CarcinomaMalignant Genitourinary System NeoplasmMalignant Solid NeoplasmPenile CarcinomaPenile Squamous Cell CarcinomaRenal Pelvis Urothelial CarcinomaSarcomatoid Renal Cell CarcinomaStage III Bladder Cancer AJCC v8Stage III Penile Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage III Renal Pelvis and Ureter Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage III Urethral Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Penile Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Renal Pelvis and Ureter Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Ureter Urothelial CarcinomaUrethral Urothelial CarcinomaClear Cell Renal Cell CarcinomaRenal Cell CarcinomaNCT02496208National Cancer Institute (NCI)152
进行中（未招募）
2 期
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryVulvar MelanomaMucosal MelanomaNCT05111574National Cancer Institute (NCI)101
已完成
2 期
Cabozantinib and Nivolumab for Carcinoid TumorsCarcinoid TumorCarcinoid Tumor of GI SystemNeuroendocrine TumorsNCT04197310Dana-Farber Cancer Institute19
招募中
2 期
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsBladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed AdenocarcinomaBladder Neuroendocrine CarcinomaBladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaChromophobe Renal Cell CarcinomaCollecting Duct CarcinomaInvasive Bladder Giant Cell Urothelial CarcinomaInvasive Bladder Lymphoepithelioma-Like CarcinomaInvasive Bladder Nested Urothelial CarcinomaInvasive Bladder Plasmacytoid Urothelial CarcinomaInvasive Bladder Sarcomatoid Urothelial CarcinomaInvasive Bladder Urothelial CarcinomaKidney Medullary CarcinomaLarge Cell Neuroendocrine CarcinomaMalignant Testicular Leydig Cell TumorMalignant Testicular Sertoli Cell TumorMetastatic Bladder CarcinomaMetastatic Bladder Clear Cell (Glycogen-Rich) Urothelial CarcinomaMetastatic Bladder Giant Cell Urothelial CarcinomaMetastatic Bladder Large Cell Neuroendocrine CarcinomaMetastatic Bladder Lipid-Rich Urothelial CarcinomaMetastatic Bladder Micropapillary Urothelial CarcinomaMetastatic Bladder Plasmacytoid Urothelial CarcinomaMetastatic Bladder Sarcomatoid Urothelial CarcinomaMetastatic Bladder Small Cell Neuroendocrine CarcinomaMetastatic Bladder Squamous Cell CarcinomaMetastatic Chromophobe Renal Cell CarcinomaMetastatic Kidney Medullary CarcinomaMetastatic Malignant Genitourinary System NeoplasmMetastatic Papillary Renal Cell CarcinomaMetastatic Penile CarcinomaMetastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Sarcomatoid Renal Cell CarcinomaMetastatic Urethral CarcinomaSarcomatoid Renal Cell CarcinomaStage IV Bladder Cancer AJCC v8Stage IV Penile Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Urachal AdenocarcinomaUrethral Clear Cell AdenocarcinomaPapillary Renal Cell CarcinomaNCT03866382National Cancer Institute (NCI)314
撤回
2 期
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaCarcinosarcoma of OvaryCarcinosarcoma of UterusCarcinosarcoma of VaginaNCT04149275University of Alabama at Birmingham